# EDGAR Filing Document

**Accession Number:** 0002038820
**File Stem:** 0000950170-25-099705
**Filing Date:** 2025-7
**Character Count:** 39953
**Document Hash:** 66b30def293c8cf7e85825fb1d744f3d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-099705.hdr.sgml**: 20250729

**ACCESSION NUMBER**: 0000950170-25-099705

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250729

**DATE AS OF CHANGE**: 20250729

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Guardian Pharmacy Services, Inc.
- **CENTRAL INDEX KEY:** 0001802255
- **STANDARD INDUSTRIAL CLASSIFICATION:** RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 200100834
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94641
- **FILM NUMBER:** 251162506

**BUSINESS ADDRESS:**
- **STREET 1:** 300 GALLERIA PARKWAY SE
- **STREET 2:** SUITE 800
- **CITY:** ATLANTA
- **STATE:** GA
- **ZIP:** 30339
- **BUSINESS PHONE:** (404) 810-0089

**MAIL ADDRESS:**
- **STREET 1:** 300 GALLERIA PARKWAY SE
- **STREET 2:** SUITE 800
- **CITY:** ATLANTA
- **STATE:** GA
- **ZIP:** 30339

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Guardian Pharmacy, LLC
- **DATE OF NAME CHANGE:** 20200204
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bindley Capital Partners I, LLC
- **CENTRAL INDEX KEY:** 0002038820

**ORGANIZATION NAME:**
- **EIN:** 352154985
- **STATE OF INCORPORATION:** IN
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 8909 PURDUE ROAD
- **STREET 2:** #500
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46268
- **BUSINESS PHONE:** (317) 704-4105

**MAIL ADDRESS:**
- **STREET 1:** 8909 PURDUE ROAD
- **STREET 2:** #500
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46268

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Guardian Pharmacy Services, Inc.**

*(Name of Issuer)*

**Class A Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**40145W101**

*(CUSIP Number)*

**Bindley Capital Partners I LLC**<br>(Attn: William E. Bindley)<br>8909 Purdue Road, Suite 500<br>Indianapolis IN 46268<br>(317) 704-4162

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**07/29/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **40145W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Bindley Capital Partners I, LLC** | Name of reporting person<br>**Bindley Capital Partners I, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**INDIANA** | Citizenship or place of organization<br>**INDIANA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**8039993.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**8039993.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**8039993.00** | Aggregate amount beneficially owned by each reporting person<br>**8039993.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**22.2%** | Percent of class represented by amount in Row (11)<br>**22.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Bindley Capital Partners I, LLC ("Bindley Capital") currently owns an aggregate of 1,939,817 shares of Class A common stock, par value $0.001 per share ("Class A common stock") and 18,300,526 shares of Class B common stock, par value $0.001 per share ("Class B common stock"), of Guardian Pharmacy Services, Inc. (the "Issuer"). Pursuant to the Issuer's Amended and Restated Certificate of Incorporation (the "Charter"), such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026.

The shares reported in Rows 7, 9 and 11 in the table above represent 1,939,817 outstanding shares of Class A common stock beneficially owned by Bindley Capital, and 6,100,176 shares of Class A common stock that will be issued to Bindley Capital on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025.

The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 12, 2025 (the "10-Q")), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.

| **CUSIP No.** | **40145W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**William E. Bindley** | Name of reporting person<br>**William E. Bindley** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**8039993.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**8039993.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**8039993.00** | Aggregate amount beneficially owned by each reporting person<br>**8039993.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**22.2%** | Percent of class represented by amount in Row (11)<br>**22.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** William E. Bindley shares voting and investment power with Thomas J. Salentine, Jr. over an aggregate of 1,939,817 shares of Class A common stock and 18,300,526 shares of Class B common stock currently owned by Bindley Capital by virtue of his position as member and officer of Bindley Capital Partners, LLC, the manager of Bindley Capital. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026.

The shares reported in Rows 8, 10 and 11 in the table above represent 1,939,817 outstanding shares of Class A common stock beneficially owned by Mr. Bindley, and 6,100,176 shares of Class A common stock that will be issued to Bindley Capital on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025.

The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.

| **CUSIP No.** | **40145W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Thomas J. Salentine, Jr.** | Name of reporting person<br>**Thomas J. Salentine, Jr.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**35714.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**8039993.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**35714.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**8039993.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**8075707.00** | Aggregate amount beneficially owned by each reporting person<br>**8075707.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**22.3%** | Percent of class represented by amount in Row (11)<br>**22.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Thomas J. Salentine, Jr. directly owns 35,714 shares of Class A common stock. Mr. Salentine, Jr. also shares voting and investment power with William E. Bindley over an aggregate of 1,939,817 shares of Class A common stock and 18,300,526 shares of Class B common stock currently owned by Bindley Capital by virtue of his position as member and officer of Bindley Capital Partners, LLC, the manager of Bindley Capital. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026.

The shares reported in Rows 7 and 9 in the table above represent 35,714 outstanding shares of Class A common stock directly owned by Mr. Salentine, Jr. The shares reported in Rows 8 and 10 represent 1,939,817 outstanding shares of Class A common stock beneficially owned by Mr. Salentine, Jr., and 6,100,176 shares of Class A common stock that will be issued to Bindley Capital on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The shares reported in Row 11 represent the aggregate amount of shares of Class A common stock beneficially owned by the Reporting Person.

The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.

| **CUSIP No.** | **40145W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Pharmacy Investors, LLC** | Name of reporting person<br>**Pharmacy Investors, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**INDIANA** | Citizenship or place of organization<br>**INDIANA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1863564.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1863564.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1863564.00** | Aggregate amount beneficially owned by each reporting person<br>**1863564.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.1%** | Percent of class represented by amount in Row (11)<br>**5.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Pharmacy Investors, LLC ("Pharmacy Investors") currently owns an aggregate of 449,624 shares of Class A common stock and 4,241,818 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026.

The shares reported in Rows 7, 9 and 11 in the table above represent 449,624 outstanding shares of Class A common stock beneficially owned by Pharmacy Investors, and 1,413,940 shares of Class A common stock that will be issued to Pharmacy Investors on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025.

The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.

| **CUSIP No.** | **40145W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**John Ackerman** | Name of reporting person<br>**John Ackerman** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1863564.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1863564.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1863564.00** | Aggregate amount beneficially owned by each reporting person<br>**1863564.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.1%** | Percent of class represented by amount in Row (11)<br>**5.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** John Ackerman has voting and investment power over an aggregate of 449,624 shares of Class A common stock and 4,241,818 shares of Class B common stock currently owned by Pharmacy Investors by virtue of his position as Manager of Pharmacy Investors, LLC. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026.

The shares reported in Rows 7, 9 and 11 in the table above represent 449,624 outstanding shares of Class A common stock beneficially owned by Mr. Ackerman, and 1,413,940 shares of Class A common stock that will be issued to Pharmacy Investors on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025.

The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.

| **CUSIP No.** | **40145W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Cardinal Equity Fund, L.P.** | Name of reporting person<br>**Cardinal Equity Fund, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**620851.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**620851.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**620851.00** | Aggregate amount beneficially owned by each reporting person<br>**620851.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.7%** | Percent of class represented by amount in Row (11)<br>**1.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Cardinal Equity Fund, L.P. ("Cardinal") currently owns an aggregate of 149,794 shares of Class A common stock and 1,413,171 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026.

The shares reported in Rows 7, 9 and 11 in the table above represent 149,794 outstanding shares of Class A common stock beneficially owned by Cardinal, and 471,057 shares of Class A common stock that will be issued to Cardinal on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. Investment and voting decisions for the shares held by Cardinal require unanimous consent of the investment committee of Cardinal Equity Partners, LLC, the general partner of Cardinal. The investment committee consists of John Ackerman, James L. Smeltzer, Peter J. Munson, Darrell E. Zink and Michael E. Smith. Therefore, no individual member of the investment committee is deemed to be the beneficial owner of the shares reported in this Schedule 13D.

The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.

| **CUSIP No.** | **40145W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Fred P. Burke** | Name of reporting person<br>**Fred P. Burke** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1711845.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1711845.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1711845.00** | Aggregate amount beneficially owned by each reporting person<br>**1711845.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.7%** | Percent of class represented by amount in Row (11)<br>**4.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Fred P. Burke currently owns an aggregate of 413,019 shares of Class A common stock and 3,896,477 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026.

The shares reported in Rows 7, 9 and 11 in the table above represent 413,019 outstanding shares of Class A common stock beneficially owned by Mr. Burke, and 1,298,826 shares of Class A common stock that will be issued to Mr. Burke on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025.

The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.

| **CUSIP No.** | **40145W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**David K. Morris** | Name of reporting person<br>**David K. Morris** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**845979.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**845979.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**845979.00** | Aggregate amount beneficially owned by each reporting person<br>**845979.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**2.3%** | Percent of class represented by amount in Row (11)<br>**2.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** David K. Morris currently owns an aggregate of 204,110 shares of Class A common stock and 1,925,608 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026.

The shares reported in Rows 7, 9 and 11 in the table above represent 204,110 outstanding shares of Class A common stock beneficially owned by Mr. Morris, and 641,869 shares of Class A common stock that will be issued to Mr. Morris on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025.

The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.

| **CUSIP No.** | **40145W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**G. Kendall Forbes** | Name of reporting person<br>**G. Kendall Forbes** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**802091.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**802091.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**802091.00** | Aggregate amount beneficially owned by each reporting person<br>**802091.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**2.2%** | Percent of class represented by amount in Row (11)<br>**2.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** G. Kendall Forbes currently owns an aggregate of 193,521 shares of Class A common stock and 1,825,710 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 7, 9 and 11 in the table above represent 193,521 outstanding shares of Class A common stock beneficially owned by Mr. Forbes, and 608,570 shares of Class A common stock that will be issued to Mr. Forbes on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Class A Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
Guardian Pharmacy Services, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
300 Galleria Parkway SE, Suite 800, Atlanta, GA, 30339

EXPLANATORY NOTE: This Schedule 13D is intended to serve as Amendment No. 2 to the Statement on Schedule 13D ("Amendment No. 2") related to the shares of Class A common stock, par value $0.001 per share ("Class A common stock") of Guardian Pharmacy Services, Inc. (the "Issuer"), and amends the initial statement on Schedule 13D filed by the Reporting Persons (as defined below) on February 3, 2025, as amended by Amendment No. 1 thereto filed on May 29, 2025, and as further amended by this Amendment No. 2 (collectively, the "Schedule 13D"). Except as specifically provided herein, this Amendment No. 2 does not modify any information previously reported in the Schedule 13D. Capitalized terms used but not defined in this Amendment No. 2 shall have the same meanings herein as are ascribed to such terms in the Schedule 13D. This Amendment No. 2 is being jointly filed by Bindley Capital Partners I, LLC ("Bindley Capital"), William E. Bindley, Thomas J. Salentine, Jr., Pharmacy Investors, LLC ("Pharmacy Investors"), John Ackerman, Cardinal Equity Fund, L.P. ("Cardinal"), Fred P. Burke, David K. Morris and G. Kendall Forbes (each a "Reporting Person," and collectively, the "Reporting Persons").

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of the date hereof, the Reporting Persons, collectively, beneficially own 13,920,037 shares of Class A common stock, representing approximately 38.4% of the shares of Class A common stock, calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q, and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.

**(b)**
The aggregate number and percentage of shares of Class A common stock beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares of Class A common stock as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on Rows 7 through 11 and Row 13 of the cover pages of this Schedule 13D and are incorporated herein by reference.

**(c)**
Except as set forth in the Schedule 13D, no transactions in the shares of Class A common stock were effected by the Reporting Persons, or, to the knowledge of the Reporting Persons, any of the persons listed on Schedule A hereto in the 60 days preceding the date of the Schedule 13D.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Bindley Capital Partners I, LLC

**Signature:** /s/ Thomas J. Salentine, Jr.

**Name/Title:** Member

**Date:** 07/29/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** William E. Bindley

**Signature:** /s/ William E. Bindley, individually

**Name/Title:** William E. Bindley, individually

**Date:** 07/29/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Thomas J. Salentine, Jr.

**Signature:** /s/ Thomas J. Salentine, Jr., individually

**Name/Title:** Thomas J. Salentine, Jr., individually

**Date:** 07/29/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Pharmacy Investors, LLC

**Signature:** /s/ John Ackerman

**Name/Title:** Managing Member

**Date:** 07/29/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** John Ackerman

**Signature:** /s/ John Ackerman, individually

**Name/Title:** John Ackerman, individually

**Date:** 07/29/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Cardinal Equity Fund, L.P.

**Signature:** /s/ John Ackerman, by Cardinal Equity Partners, LLC, its General Partner

**Name/Title:** Managing Member

**Date:** 07/29/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Fred P. Burke

**Signature:** /s/ Fred P. Burke, individually

**Name/Title:** Fred P. Burke, individually

**Date:** 07/29/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** David K. Morris

**Signature:** /s/ David K. Morris, individually

**Name/Title:** David K. Morris, individually

**Date:** 07/29/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** G. Kendall Forbes

**Signature:** /s/ G. Kendall Forbes, individually

**Name/Title:** G. Kendall Forbes, individually

**Date:** 07/29/2025